Clinical Trial Update: Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing single-dose PF-05089771 for efficacy and safety in inherited erythromelalgia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Erythromelalgia

Drugs mentioned

• PF-05089771 (PF-05089771)

Snippet

Sponsor: Pfizer | Conditions: Inherited Erythromelalgia | Phase 2 | Status: COMPLETED | Results posted: 2019-11-19